Rocket Pharmaceuticals is trading 9.77% up at $3.82 after opening the September 11, 2026 pre-market session higher following a broader risk-on tone.
- The company presented at the Cantor Global Healthcare Conference on September 10, highlighting Danon disease program progress and favorable safety results in three patients.
- No new company-specific filing or definitive catalyst explaining the full move was identified. Confidence is medium.